CM Life Sciences III Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cambridge, mass.--(business wire)--eqrx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner cstone pharmaceuticals' phase 3 gemstone-302 study at the international association for the study of lung cancer 2021 world conference on lung cancer (iaslc 2021 wclc). gemstone-302 is a placebo-controlled phase 3 trial evaluating

Cambridge, mass. & new york--(business wire)--eqrx, inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and cm life sciences iii, inc. (nasdaq: cmltu), a life science-focused special purpose acquisition company, or spac, sponsored by affiliates of casdin capital, llc and corvex management lp, today announced that they have entered into a definitive business combination agreement. the transaction is expe

New york--(business wire)--cm life sciences iii inc. (nasdaq: cmltu) (the “company”) today announced that holders of the company's units sold in its initial public offering may elect to separately trade the shares of class a common stock and redeemable warrants included in its units commencing on or about may 28, 2021. the shares of class a common stock and warrants that are separated will trade on the nasdaq capital market (“nasdaq”) under the symbols “cmlt” and “cmltw,” respectively. those un

New york--(business wire)--cm life sciences iii inc. (the “company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-allotment option. the units are listed on the nasdaq capital market (“nasdaq”) and began trading under the ticker symbol “cmltu” on april 7, 2021. each unit consists of one share of class a common stock and one-fifth of one redeemabl

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals' Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer (IASLC 2021 WCLC). GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. The transaction is expe

NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (Nasdaq: CMLTU) (the “Company”) today announced that holders of the Company's units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about May 28, 2021. The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “CMLT” and “CMLTW,” respectively. Those un

— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.

Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.

NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-allotment option. The units are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “CMLTU” on April 7, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemabl